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Relapse is least common in patients with indolent B cell (iB) malignancies (ie, iB non-Hodgkin lymphoma
[NHL]) who undergo nonmyeloablative allogeneic transplantation (NMAT) in complete remission (CR).
However, for the many patients unable to achieve this state, outcomes are poorly described and methods to
improve results are unknown. We sought to describe the long-term follow-up and predictive factors for these
poor-risk patients unable to achieve CR before NMAT. We identiﬁed and evaluated patients with iB-NHL
including chronic lymphocytic leukemia treated with ﬂudarabine/total body irradiationebased NMAT that
had evidence of persistent disease before NMAT. From December 1998 to April 2009, 89 patients were
identiﬁed, most commonly with small/chronic lymphocytic lymphoma (n ¼ 62) and follicular lymphoma
(n ¼ 24). Pretransplant anti-CD20 radioimmunotherapy (RIT) using standard yttrium-90-ibritumomab
tiuxetan was administered to 18 patients (20%) who more frequently had chemoresistant disease (81%
versus 39%, P ¼ .003), disease bulk > 5 cm (61% versus 15%, P < .001), thrombocytopenia < 25k/mL (33% versus
7%, P ¼ .002), and Hematopoietic Cell Transplant Comorbidity Index scores  3 (72% versus 37%, P ¼ .006).
After adjusting for these imbalances, RIT-treated patients had improved rates of progression-free survival
(PFS) (hazard ratio [HR] ¼ .4; 95% conﬁdence interval [CI], .2 to .9, P ¼ .02) and overall survival (OS) (HR ¼ .3;
95% CI, .1 to .8, P ¼ .008) compared with the non-RIT group. The 3-year adjusted estimates of PFS and OS for
the RIT and non-RIT groups were 71% and 87% versus 44% and 59%, respectively. The use of RIT was the only
factor independently associated with improved PFS and OS. Rates of nonrelapse mortality and graft-versus-
host disease (GVHD) were similar between the 2 groups, although over 70% of patients developed clinically
signiﬁcant acute or chronic GVHD. In conclusion, despite relatively high rates of GVHD, patients with
persistent iB-NHL can derive durable beneﬁt from NMAT.
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Nonmyeloablative allogeneic hematopoietic cell trans-
plantation (NMAT) is frequently cited as the only potentially
curative intervention for advanced-stage indolent B cell non-dgments on page 286.
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ty for Blood and Marrow Transplantation.Hodgkin lymphomas (iB-NHL) and chronic lymphocytic
leukemia (CLL). These results have been demonstrated
consistently in a number of series, with long-term relapse-
free survival rates ranging from about 40% to 80% [1-7].
Furthermore, low rates of regimen-related toxicity and
nonrelapse mortality (NRM) after NMAT make it feasible for
older and/or more medically inﬁrm patients. Improved
methods of HLA typing and medical prophylaxis have also
reduced the rates of severe graft-versus-host disease
(GVHD), the most common complication of this treatment
[8,9].
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relapse remains the major concern after NMAT, particularly
for patients with persistent/refractory disease at the time of
transplantation with bulky disease sites [1,5]. Thus, it is
believed that being in complete remission (CR) at the time of
NMAT yields lower rates of relapse [2]. However, for patients
with chemotherapy-refractory disease, the use of high-dose
chemotherapy-based conditioning may be contemplated to
achieve this goal. Unfortunately, identifying a regimen with
effective antitumor activity in this setting remains chal-
lenging. Moreover, the risk of NRM may be prohibitive for
such an approach, which can be estimated with tools such as
the Hematopoietic Cell Transplantation Comorbidity Index
(HCT-CI) [10].
Radioimmunotherapy (RIT) is 1 strategy to augment
NMAT, which delivers a therapeutic radionuclide to an
antigen expressed on tumor cells via a monoclonal antibody.
Anti-CD20 RIT-augmented NMAT using yttrium-90 (90Y)-
ibritumomab tiuxetan has been studied by our group and
others, based on the hypothesis that chemoresistant tumors
may remain radiosensitive, and achieving an early post-
transplant CR with this approach could lead to better long-
term outcomes [11-16]. These studies suggested the best
outcomes were in patients with indolent histologies despite
frequent high-risk clinical features, such as chemorefractory
and bulky disease. However, to date, no formal comparative
evaluation has been conducted to determine if such
an approach is superior to more standard conditioning
regimens.
To address this question and to better understand the
utility of NMAT in patients with persistent iB-NHL, we
identiﬁed a cohort of patients treated at our center meeting
eligibility requirements of our prior RIT-NMAT trial but for
other reasons did not enroll. These patients could then serve
as a fair standard-treatment comparator to the RIT group.
Herein, we describe the long-term outcomes for this unique
population of patients and evaluate the impact of a RIT-
augmented conditioning regimen on results.Table 1
Baseline Characteristics of Patents Who Underwent NMAT for Persistent Indolent
Patient Characteristic Total (N ¼ 89)
N %
Gender
Male 66 74
Female 23 26
Age, yr
Median 56
Range 30-68
Histology
CLL/SLL 62 70
FL 24 27
Othery 3 3
Number of prior therapies
Median 4
Range 1-12
Prior rituximab 78 88
Prior autologous transplant 16 18
Chemoresistantz 38 48
Bulky disease (>5 cm) 22 25
HCT-CI score  3 39 44
Unrelated donor 42 47
Pre-NMAT platelet count < 25k/mL 11 12
FL indicates follicular lymphoma.
* P values are from comparisons between the RIT and control groups.
y RIT group: marginal zone lymphoma (n ¼ 1) and hairy cell leukemia (n ¼ 1);
z Response to the last systemic therapy administered before NMAT was not avaMETHODS
Study Cohort
We identiﬁed patients over age 18 years who presented to
the University of Washington and Fred Hutchinson Cancer
Research Center between December 1998 and April 2009 for
NMAT as treatment for an iB malignancy, including CLL,
follicular lymphoma, small lymphocytic lymphoma (SLL),
marginal zone lymphoma, and hairy cell leukemia. We
further selected patients with detectable disease at the time
of NMAT, as assessed by imaging studies according to stan-
dard International Working Group deﬁnitions [17,18] or via
ﬂow cytometric analysis of peripheral blood or bonemarrow.
We excluded patients without evidence of disease, with
large-cell histologic transformation, and who received NMAT
from an HLA-mismatched donor. To control for potential
imbalances, patients were only included in this analysis if
theymet the eligibility criteria for the RIT-based NMATstudy,
regardless of which treatment they received. For patients not
treated on the RIT study, reasons they did not enroll included
referral for NMAT outside of the enrollment period of this
study, insurance denial, or preference of the treating physi-
cian or patient. Most patients included in this analysis were
also included in prior publications by our group [4,5,13], but
this report includes an additional 2 years of patients treated
with standard NMAT and up to 5 additional years of post-
NMAT follow-up for those studied previously.
All patients received conditioning with ﬂudarabine
30 mg/m2 for 3 days followed by 200 cGy total body irradi-
ation, as previously described [4]. Patients in the RIT group
also received the following, as previously published [13]: On
day e21 before transplantation, 250 mg/m2 of rituximabwas
administered before an imaging dose of 111In-ibritumomab
tiuxetan to ensure expected biodistribution. On day e14,
250 mg/m2 of rituximab was administered before .4 mCi/kg
of 90Y-ibritumomab tiuxetan, with a maximum dose of
32 mCi. Postgrafting immunosuppression varied based on
the speciﬁc protocol on which patients were treated, but all
were based on the combination of a calcineurin inhibitor (ie,B Cell Malignancies
RIT Group (n ¼ 18) Control Group
(n ¼ 71)
P*
N % N %
.69
14 78 52 73
4 22 19 27
.95
58 55
30-68 35-67
.08
10 56 52 73
6 33 18 25
2 11 1 1
.58
4 4
3-12 1-11
18 100 60 85 .07
4 22 12 17 .60
13 81 25 39 .003
11 61 11 15 < .001
13 72 26 37 .006
12 67 30 42 .06
6 33 5 7 .002
control group: marginal zone lymphoma (n ¼ 1).
ilable from 9 patients (2 from the RIT group and 7 from the control group).
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patients treated on an investigational study signed a consent
form approved by the Human Subjects Committee of the
University of Washington and/or the Institutional Review
Board of the Fred Hutchinson Cancer Research Center in
accordance with the Declaration of Helsinki. In addition,
separate institutional approval was obtained for this analysis
to retrospectively gather data from patient records and
databases.Study Variables
Baseline (ie, pre-NMAT) demographic information,
including age, sex, diagnosis (according to the World Health
Organization classiﬁcation for lymphoid neoplasms [19]), he-
matopoietic cell donor source, number of prior chemotherapy
regimens, prior treatment with rituximab, prior autologousFigure 1. Survival of 89 patients who underwent NMAT for persistent indolent B c
followed by comparisons based on (B) disease bulk, (C) histology, (D) hematopoietic c
with CLL/SLL).transplantation, and pre-NMAT platelet count, was identically
collected for the entire group. Patients were considered to
have bulky disease if a tumor > 5 cm in largest diameter was
noted on pre-NMAT computed tomography scan. HCT-CI
scores were calculated as previously described [10]. Chemo-
resistant diseasewas deﬁned as not achieving at least a partial
remission to the last systemic therapyadministered, according
to InternationalWorking Group deﬁnitions [17,18]. Follow-up
was updated as of September 2013.Endpoints and Statistical Considerations
Progression-free survival (PFS), overall survival (OS), and
NRM were calculated from the date of transplantation,
where PFS was deﬁned as a lack of relapse, progression, or
death from any cause. Time of onset and severity of acute and
chronic GVHD were deﬁned according to standardizedell malignancies. Kaplan-Meier curves depict (A) PRS and OS of all patients,
ell donor source, and (E) cytogenetic risk. (Panel E only includes those patients
Table 2
Univariate Analysis of PFS Between Subgroups of Patients with Persistent
Indolent B Cell Malignancies Undergoing NMAT
n Median
PFS (mo)
3-Year
PFS
HR (95% CI) P
No RIT 71 19.0 44% 1.0
RIT 18 53.0 56% .7 (.4-1.5) .36
Disease bulk  5 cm 67 30.8 49% 1.0
Disease bulk > 5 cm 22 14.8 36% 1.5 (.9-2.7) .15
Other histologies 27 18.1 37% 1.0
CLL/SLL 62 23.8 50% .8 (.5-1.5) .56
Related donor 47 37.6 53% 1.0
Unrelated donor 42 19.0 38% 1.1 (.7-1.8) .76
Nonehigh-risk cytogenetics* 33 53.0 61% 1.0
High-risk cytogenetics* 14 19.9 43% 1.2 (.5-2.8) .63
* “High-risk cytogenetics” were those patients with CLL/SLL who
harbored deletion 11q and/or deletion 17p; all others with CLL/SLL from
whom cytogenetic data were available were considered “nonehigh-risk.”
Table 3
Multivariable Analysis of Factors Imbalanced Between the RIT and Control
Groups
OS (49 events) PFS (59 events)
HR (95% CI) P HR (95% CI) P
RIT .3 (.1-.8) .008 .4 (.2-.9) .02
Unrelated donor 1.1 (.6-1.9) .76 1.2 (.7-2.0) .54
Bulky disease (>5 cm) 2.4 (1.1-4.8) .03 1.9 (1.0-3.7) .06
Pre-NMAT platelet count
< 25k/mL
1.4 (.6-3.2) .41 2.1 (1.0-4.4) .06
HCT-CI score  3 1.5 (.8-2.7) .22 1.4 (.8-2.4) .30
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with systemic immunosuppression for late acute or chronic
GVHD by National Institutes of Health criteria [22]. Fre-
quencies of characteristics between groups were compared
using a chi-square test, whereasmeanswere compared using
aWilcoxon rank sum text. Kaplan-Meier curves were used to
estimate the probabilities of OS and PFS; cumulative inci-
dence estimates were calculated for acute and chronic GVHD
and NRM. The statistical signiﬁcance of differences in event
rates was evaluatedwith the proportional hazards regression
model. All P values are based on the Wald statistic and are 2-
sided. To account for imbalanced covariates in subgroups,
adjusted estimates of PFS, OS, and cumulative incidences of
NRM and acute and chronic GVHDwere generated according
to previously published methods [23].
RESULTS
Patient Characteristics
We identiﬁed 89 patients from our center who were
treated with ﬂudarabine/total body irradiationebased NMAT
for iB-NHL or CLL with persistent disease at the time of
transplantation. Eighteen patients (20%) received RIT-
augmented NMAT and are hereafter referred to as the RIT
group; they constituted all patients with nontransformed
indolent histologies whowere treated on our previous phase
II study of this approach [13]. The remaining 71 patients
(80%) met eligibility criteria for this clinical trial (ie, histo-
logically conﬁrmed CD20þ B-NHL or CLL with persistent
disease and an HLA-matched peripheral blood stem cell
donor) and are hereafter referred to as the control group. All
but 2 of these 71 patients (97%) were enrolled on an alter-
native prospective clinical trial at our center.
The baseline characteristics of these 89 patients with
persistent pretransplant disease are summarized and
compared in Table 1. Most patients in this cohort were men,
over age 50 years, and had CLL/SLL. Beyond the presence of
persistent disease, these patients generally had several other
high-risk features. They were relatively heavily pretreated,
with a median of 4 prior chemotherapy regimens before
NMAT, with a large majority having received rituximab as
part of this prior treatment. Nearly half had chemoresistant
disease, and 1 in 4 had bulky sites of disease. Among the 47
patients with CLL/SLL from whom cytogenetic data were
available, 14 (30%) harbored high-risk cytogenetic abnor-
malities: 8 (17%) had a deletion at 11q, 5 (11%) had a deletion
at 17p, and 1 (2%) had deletions at both loci.
Outcomes of iB-NHL with Pretransplant Persistent
Disease
PFS and OS for these 89 patients, as well as PFS from
selected subgroups, are depicted in Figure 1. The median PFS
and OS for the group as a whole were 23.4 months and
76.5 months, respectively, whereas the 3-year rates of PFS
and OS were 46% and 63%, respectively, with a median
follow-up of 6.8 years. Table 2 shows unadjusted compari-
sons between the various subgroups investigated. Among
these, the largest apparent difference was observed between
the patients with or without bulky disease > 5 cm (median
PFS: 14.8 versus 30.8 months, respectively; hazard ratio
[HR] ¼ 1.5; 95% conﬁdence interval [CI], .9 to 2.7). However,
this difference was not statistically signiﬁcant (P ¼ .15).
Comparison of RIT versus Control Groups
Patients in the RIT group were more likely to have high-
risk features than those in the control group (Table 1), withsigniﬁcantly more chemoresistant (81% versus 39%, P ¼ .003)
and bulky disease (61% versus 15%, P < .001), high-risk HCT-
CI scores (72% versus 37%, P ¼ .006), and low pre-NMAT
platelet count (33% versus 7%, P ¼ .002). Multivariate anal-
ysis, adjusting for factors with greatest imbalance between
groups (Table 3), demonstrated signiﬁcant improvement in
both PFS (HR ¼ .4; 95% CI, .2 to .9; P ¼ .02) and OS (HR ¼ .3;
95% CI, .1 to .8; P ¼ .008) in the RIT group. Chemoresistance
was highly correlated with bulky disease and not included in
the multivariate analysis. Model-based adjusted estimates of
PFS and OS for the RIT group are shown in Figure 2A,B,
respectively, along with unadjusted Kaplan-Meier estimates.
The adjusted estimates show the predicted PFS and OS for a
group of RIT patients with the same covariate characteristics
as the control group. The 3-year adjusted estimates of PFS
and OS for the RIT group were 71% and 87%, compared with
44% and 59% for the control group, respectively.NRM and GVHD
We found no signiﬁcant difference in rates of NRM be-
tween the RIT and control groups (HR ¼ .5; 95% CI, .2 to 1.8,
P ¼ .32; Figure 3A). In addition, no difference in the cumu-
lative incidence of clinically signiﬁcant (ie, grades II to IV)
acute GVHD (HR ¼ 1.0; 95% CI, .6 to 1.9; P ¼ .88) or chronic
GVHD (HR ¼ 1.1; 95% CI, .6 to 2.0; P ¼ .76) between these 2
groups (Figure 3B,C, respectively) was noted. Among patients
who were alive and disease-free 1 year after NMAT, 14 of 15
patients (93%) in the RIT group and 37 of 44 (84%) in the
control group developed chronic GVHD. Similar to above, we
compared the rates of these events after adjustment for
potentially confounding factors between the RIT and control
groups: for NRM, we adjusted for age  50, HCT-CI  3,
number of prior therapies  5, and donor relation; for acute
and chronic GVHD, we adjusted for age and donor relation.
Figure 2. Outcomes are signiﬁcantly improved with the addition of anti-CD20 RIT to NMAT for persistent indolent B cell malignancies, after adjusting for imbalanced
covariates. Kaplan-Meier curves depict rates of (A) PFS and (B) OS in the control and RIT groups. The solid lines depict the observed outcomes for the control and RIT
groups. The dashed lines reﬂect the adjusted estimates, showing the hypothetical PFS and OS rates for a group of RIT patients with the same covariate characteristics
as the control group.
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justed HRs for NRM (HR¼ .4; 95% CI, .2 to 1.5; P¼ .18), grades
II to IV acute GVHD (HR ¼ .9; 95% CI, .5 to 1.7; P ¼ .73), and
chronic GVHD (HR ¼ 1.1; 95% CI, .6 to 2.0; P ¼ .82). Although
not speciﬁcally assessed here, details regarding engraftment
and toxicity among these patients have been reportedly
previously and were similarly comparable between RIT and
control groups [4,5,13].
DISCUSSION
We describe the long-term outcomes (6.8 years median
follow-up) after NMAT for patients with persistent iB-NHL orFigure 3. The addition of anti-CD20 RIT does not signiﬁcantly increase the rate of ser
rates of (A) NRM, (B) grades II to IV acute GVHD, and (C) chronic GVHD in the controCLL and demonstrate 2 key ﬁndings: such an approach can
yield long-term remissions in a large proportion of these
seemingly high-risk patients and improved results may be
obtained after addition of standard doses of 90Y-ibritumo-
mab tiuxetan. Even though attempts are typically made to
induce a CR with salvage therapies before NMAT, many pa-
tients cannot achieve this goal, supported by the fact that the
largest cohorts described to date include a substantial pro-
portion of patients not in CR [1-7]. Further, a subset of these
patients with refractory disease are likely being denied
transplant for this reason. Our data, which to our knowledge
are the ﬁrst to speciﬁcally examine this relatively commonious toxicity after NMAT. Kaplan-Meier curves depict the cumulative incidence
l and RIT groups.
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patients.
In our analyses, we attempted to identify the key factors
that may predict outcome for this inherently high-risk pop-
ulation. Interestingly, the only factor associated with signif-
icantly better PFS and OS rates in a multivariate analysis was
the addition of RIT (Table 3). From our results, we identiﬁed 1
of the ﬁrst disease-speciﬁc manipulations to a NMAT plat-
form that can signiﬁcantly improve outcome. This conclusion
was suggested previously in a similar study [16]: In patients
with follicular lymphoma undergoing NMAT, these authors
concluded that the addition of anti-CD20 RIT seemed to
overcome the negative prognostic impact of chemorefractory
disease. Unlike our ﬁndings here, no formal statistical ana-
lyses were performed to objectively demonstrate beneﬁt
from such an approach.
The potential beneﬁt of RIT is particularly notable in our
study given the preponderance of patients with CLL/SLL and
the relatively low level of CD20 expression typical of this
disease. It has long been known that even low doses of ra-
diation can be exquisitely effective in CLL/SLL [24]. However,
evaluation of RIT in patients with active disease outside the
transplant setting has been limited because of the risk for
prolonged hematopoietic toxicity in the setting of extensive
marrow involvement or baseline cytopenias. Our study
would suggest the pretransplant use of RIT may represent
the optimal use of this modality in CLL/SLL with marrow
involvement, particularly because the degree of marrow
involvement was not factored into eligibility for our RIT-
based approach [13].
We concede that the limited sample size and non-
randomized nature of our study does not deﬁnitively estab-
lish that anti-CD20 RIT should be used before NMAT in all
patients. It is notable that in over a decade of NMAT at our
center, we were only able to identify 89 such patients,
potentially suggesting that many patients unable to achieve
CR are not referred for transplant because of perceived poor
outcomes. This premise is particularly important in the cur-
rent era of novel B cell receptor signaling pathway targeted
agents such as ibrutinib and idelalisib, which typically induce
high overall response and disease control rates but rarely
yield CRs and are not curative [25-28]. Our data would sug-
gest that these drugs could still be used as a successful bridge
to transplant while donors are being identiﬁed despite
resultant persistent disease.
In conclusion, our data indicate that despite the negative
prognostic impact of persistent disease at the time of NMAT,
a lack of CR should not be a contraindication to transplant,
with 46% of our patients with iB-NHL or CLL/SLL alive and
progression-free at 3 years. The addition of 90Y-ibritumomab
tiuxetan appears to further improve both PFS and OSwithout
additional appreciable toxicity. These ﬁndings are particu-
larly relevant in the current era of novel therapeutics and set
the stage for a prospective randomized trial of standard
versus RIT-augmented NMAT in nonremission patients with
indolent B cell malignancies.
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